ChemicalBook > Product Catalog >API >Nervous system drugs >Antiparkinson Drugs >Bromocriptine mesylate

Bromocriptine mesylate

Bromocriptine mesylate Suppliers list
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: +86-0371-55170693 +86-19937530512
Products Intro: Product Name:TIANFU-CHEM CAS NO.22260-51-1 Bromocriptine mesylate
Purity:99% Package:25KG;5KG;1KG
Company Name: Shanxi Naipu Import and Export Co.,Ltd
Tel: +86-13734021967 +8613734021967
Products Intro: Product Name:Bromocriptine mesylate
Purity:99% Package:1ASSAYS;10USD
Tel: +86 18953170293
Products Intro: Product Name:Bromocriptine mesylate
Purity:0.99 Package:5KG;1KG
Company Name: BOC Sciences
Tel: +16314854226
Products Intro: Product Name:Bromocriptine Mesylate
Purity:98% Package:500 mg Remarks:Bromocriptine mesylate is the mesylate salt of Bromocriptine. It is a dopamine receptor agonist. It is a derivative of the ergotoxin group of ergot alkaloids.
Tel: +8618523575427
Products Intro: Product Name:bromocriptine mesylate
Purity:0.99 Package:1kg

Bromocriptine mesylate manufacturers

  • Bromocriptine mesylate
  • $10.00 / 1ASSAYS
  • 2022-02-25
  • CAS:22260-51-1
  • Min. Order: 1ASSAYS
  • Purity: 99%
  • Supply Ability: 500tons/month
  • CB-154 mesylate
  • $5.00 / 1KG
  • 2022-02-24
  • CAS:22260-51-1
  • Min. Order: 0.5KG
  • Purity: >99%
  • Supply Ability: 20tons
Bromocriptine mesylate Basic information
Product Name:Bromocriptine mesylate
Product Categories:PARLODEL;Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Dopamine receptor
Mol File:22260-51-1.mol
Bromocriptine mesylate Structure
Bromocriptine mesylate Chemical Properties
Melting point 192-196° (dec)
alpha D20 +95° (c = 1 in methanol-methylene chloride)
storage temp. 2-8°C
solubility H2O: 0.8 mg/mL
form solid
pka4.90(at 25℃)
color white
optical activity[α]20/D +95°, c = 1 in methanol: methylene chloride (1:1)(lit.)
Merck 13,1400
BRN 4115238
Stability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months
CAS DataBase Reference22260-51-1(CAS DataBase Reference)
Safety Information
Hazard Codes Xn
Risk Statements 20/21/22
Safety Statements 22-24/25-36
WGK Germany 3
RTECS KE1595000
HS Code 29396900
ToxicityLD50 in mice, rats, rabbits (mg/kg): 190, 72, 12.5 i.v. (Parkes)
MSDS Information
SigmaAldrich English
Bromocriptine mesylate Usage And Synthesis
DescriptionBromocriptine is a dopamine receptor agonist (Kis = 1,659, 12.2, 12.2, 59.7, and 1,691 nM for dopamine D1, D2, D3, D4, and D5 receptors, respectively). It also binds to the serotonin (5-HT) receptor subtypes 5-HT1A and 5-HT1D (Kis = 12.9 and 10.7 nM, respectively), as well as α1-adrenergic receptors (Kis = 1.12-4.17 nM). Bromocriptine (5 mg/kg) restores locomotor activity, without inducing dyskinesia, in a macaque model of Parkinson’s disease induced by MPTP. Formulations containing bromocriptine have been used in the treatment of Parkinson''s disease, hyperprolactinemia-associated dysfunctions, and acromegaly.
Chemical PropertiesSolid
Uses2-Bromo-α-Ergocryptine is a dopamine receptor agonist. 2-Bromo-α-Ergocryptine is a derivative of the ergotoxin group of ergot alkaloids. 2-Bromo-α-Ergocryptine is a prolactin inhibitor; antiparkinsoni an.
UsesDopamine receptor agonist; derivative of the ergotoxin group of ergot alkaloids. Prolactin inhibitor; antiparkinsonian.
Uses2-Bromo-α-ergocryptine methanesulfonate salt has been used:
  • as D2 agonist in bird zebra finches
  • for Prl secretion inhibitor in mice
  • for the inhibition of motility in planaria worm

Manufacturing ProcessA solution of 3.4 grams of N-bromosuccinimide in 60 cc of absolute dioxane is added drop wise in the dark, during the course of 5 minutes, to a stirred solution, heated to 60°C, of 9.2 grams of ergocryptine in 180 cc of absolute dioxane. The reaction mixture is stirred at this temperature for 70 minutes and is concentrated to a syrup-like consistency in a rotary evaporator at a bath temperature of 50°C. The reaction mixture is subsequently diluted with 300 cc of methylene chloride, is covered with a layer of about 200 cc of a 2 N sodium carbonate solution in a separating funnel and is shaken thoroughly. The aqueous phase is extracted thrice with 100 cc amounts of methylene chloride. The combined organic phases are washed once with 50 cc of water, are dried over sodium sulfate and the solvent is removed under a vacuum.
The resulting brown foam is chromatographed on a 50-fold quantity of aluminum oxide of activity II-III with 0.2% ethanol in methylene chloride as eluant, whereby the compound indicated in the heading is eluted immediately after a secondary fraction which migrates somewhat more rapidly than the fractions containing the heading compound. The last fractions to leave the aluminum oxide contain varying amounts of starting material together with the heading compound, and may be subjected directly, as mixed fractions, to an afterbromination in accordance with the method described above. The fractions containing the pure heading compound are combined and crystallized from methyl ethyl ketonehopropy1 ether. Melting point 215°-218°C (decomp.), [α]D 20-195° (c = 1 in methylene chloride).
Brand nameParlodel (Novartis).
Therapeutic FunctionProlactin inhibitor
General DescriptionBromocriptine mesylate,(6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate(Parlodel), is a white solid soluble in ethanol and slightly solublein water (pKa’s=6.6 and 15). Bromocriptine is rapidlyabsorbed after oral administration and it has low systemicbioavailability because of its extensive first-pass metabolism.Bromocriptine enters the brain quickly with a half-lifefor uptake into the brain of approximately 0.3 hours; 8% ofthe drug crosses the BBB.The metabolites are excreted primarilyin the bile and feces. The high first-pass hepatic metabolismimplies an increased risk of drug interactions.Concomitant administration with the DA antagonists, metoclopramide,or domperidone may aggravate parkinsoniansymptoms and induce extrapyramidal side effects (EPS).Other drugs that may interact with bromocriptine are highlyplasma protein–bound drugs (e.g., warfarin, increased dyskinesiacaused by bromocriptine); macrolides antibacterials(enhanced dopaminergic effects); and caffeine (elevation inplasma bromocriptine concentrations). The combination oflevodopa/AADC inhibitors with bromocriptine permits a reductionof the dose of levodopa. Thus, the side effects oflevodopa are decreased, resulting in a more continuous stimulationof DA receptors.
Biological ActivitySelective D 2 -like dopamine receptor agonist (K i values are ~ 8, ~ 5, ~ 290, ~ 440 and ~ 450 nM for D 2 , D 3 , D 4 , D 1 and D 5 receptors respectively).
Biochem/physiol ActionsBromocriptine is an ergot alkaloid and a dopamine D2 receptor agonist. It is prescribed for Parkinson′s disorder, hyperprolactinemia and galactorrhoea. It modulates β cells of the pancreas from insulin hypersecretion and improves the metabolic profile in type 2 diabetes patients with obesity. It also modulates glutamate release by glutamate transporter,GLT-1.
Veterinary Drugs and TreatmentsBromocriptine may potentially be of benefit in treating acromegaly/ pituitary adenomas or pseudopregnancy in a variety of species. However, because of adverse effects, its potential value for treating hyperadrenocorticism in dogs is low. It has been used in dogs for pregnancy termination and pseudopregnancy.
References1) Nilsson and Hokfelt (1978), Effect of the dopamine agonist bromocriptine on blood pressure, catecholamines and renin activity in acromegalics at rest, following exercise, and during insulin induced hypoglycemia; Acta Endocrinol., Supp. 216 83 2) Seeman and Van Tol (1994), Dopamine receptor pharmacology; Trends Pharmacol. Sci., 15 264 3) Carvalho et al. (2015), Maternal prolactin inhibition causes changes in leptin at 22- and 30-day old pups; Horm. Metab. Res., 47 528 4) Hubner and Koob (1990), Bromocriptine produces decreases in cocaine self-administration in the rat; Neuropsychopharmacol., 3 101
Bromocriptine mesylate Preparation Products And Raw materials
Raw materialsALPHA-ERGOCRYPTINE-->N-Bromosuccinimide
Tag:Bromocriptine mesylate(22260-51-1) Related Product Information
ALPHA-ERGOCRYPTINE BroMocriptine IMpurity E Bromocriptine Impurity 2 (8S)-2-BroMo α-Ergocryptine 5'alpha(S)-sec-butyl-12'-hydroxy-2'-isopropylergotaman-3',6',18-trione Bromocriptine Impurity A (Mixture of Diastereomers) Ergoline-8-carboxylic acid, 2-bromo-9,10-didehydro-6-methyl-, (8β)- BroMocriptine IMpurity F BroMocriptine-13C-d3 BroMocriptine IMpurity G Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (2'β,5'α,8α)- (9CI) Bromocriptine methanesulfonate 4-(2-HYDROXYETHYL)-PIPERAZIN-2-ONE 1-Butylpiperazine 2-Ethylpiperazine (1-BUTYL-2-PYRROLIDINYL)-N-METHYLMETHANAMINE N,N'-DIACETYLETHYLENEDIAMINE